Ipsen (pharmaceutical company)
GPTKB entity
Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:David_Loew
|
| gptkbp:founded |
1929
|
| gptkbp:founder |
gptkb:Henri_Beaufour
|
| gptkbp:headquartersLocation |
gptkb:Paris,_France
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ipsen (pharmaceutical company)
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:listedOn |
gptkb:CAC_Mid_60
|
| gptkbp:notableProduct |
gptkb:Decapeptyl
gptkb:Somatuline gptkb:Dysport |
| gptkbp:numberOfEmployees |
over 5,000
|
| gptkbp:officialWebsite |
https://www.ipsen.com/
|
| gptkbp:operatesIn |
over 115 countries
|
| gptkbp:parentCompany |
gptkb:Beaufour_family
|
| gptkbp:products |
oncology drugs
rare disease drugs neuroscience drugs |
| gptkbp:revenue |
2.9 billion euros (2022)
|
| gptkbp:stockExchange |
gptkb:Euronext_Paris
|
| gptkbp:stockSymbol |
gptkb:IPN
|
| gptkbp:bfsParent |
gptkb:IPSEN_Foundation
|
| gptkbp:bfsLayer |
8
|